Institutional members access full text with Ovid®

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib

Ariyasu, Ryo; Horiike, Atsushi; Koyama, Junji; Saiki, Masafumi; Sonoda, Tomoaki; Kawashima, Yosuke; Takano, Natsuki; Oguri, Tomoyo; Nishikawa, Shingo; Kitazono, Satoru; Yanagitani, Noriko; Ohyanagi, Fumiyoshi; Nishio, Makoto

doi: 10.1097/CAD.0000000000000489
Case Report

In patients with non-small-cell lung cancer harboring an epithelial growth factor receptor (EGFR) active mutation, central nervous system progression after a response to EGFR tyrosine kinase inhibitors is frequent. Central nervous system metastasis, especially leptomeningeal carcinomatosis (LMC), is a serious complication and no standard treatment has been established for LMC. Here, we report two cases in which the addition of bevacizumab to erlotinib enhanced the efficacy against LMC; as a result, radiographic abnormalities decreased markedly and symptoms were well controlled. This combination treatment may be useful to treat LMC in patients with EGFR-positive non-small-cell lung cancer.

Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

Correspondence to Makoto Nishio, MD, PhD, Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, JapanTel: +81 3 3520 0111; fax: +813 3520 0141; e-mail: mnishio@jfcr.or.jp

Received November 7, 2016

Accepted February 6, 2017

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.